MRK.DE - MERCK Kommanditgesellschaft auf Aktien

XETRA - XETRA Delayed Price. Currency in EUR
89.76
+0.66 (+0.74%)
At close: 5:35PM CEST
Stock chart is not supported by your current browser
Previous Close89.10
Open89.38
Bid0.00 x 6700
Ask0.00 x 11200
Day's Range89.18 - 90.32
52 Week Range74.54 - 100.95
Volume550,626
Avg. Volume592,092
Market Cap38.965B
Beta0.91
PE Ratio (TTM)16.15
EPS (TTM)5.56
Earnings DateNov 14, 2018
Forward Dividend & Yield1.25 (1.47%)
Ex-Dividend Date2018-04-30
1y Target EstN/A
  • Deleveraging Still Remains a Top Priority, Says Merck KGaA's CFO
    Bloomberg Video5 days ago

    Deleveraging Still Remains a Top Priority, Says Merck KGaA's CFO

    Aug.09 -- Marcus Kuhnert, chief financial officer at Merck KGaA, discusses second-quarter earnings, market share in liquid crystals, their M&A path and the drivers of their life sciences unit. He speaks on "Bloomberg Markets: European Open."

  • The Wall Street Journal5 days ago

    [$$] Germany's Merck Boosts Hedges Against Currency Gyrations

    KGaA ramped up its currency hedging efforts in recent months as wild swings in exchange rates took a bite out of earnings. Merck hedges between 30% and 70% of its expected currency exposure over the next 12 months, and the company is close to the upper end of that range now, Mr. Kuhnert said.

  • The Wall Street Journal5 days ago

    [$$] Merck KGaA Renews Commitment to U.S. Presence

    KGaA (MRK.XE) on Thursday voiced concerns about barriers to free trade and highlighted a renewed commitment to its presence in the U.S., where it has been increasing its workforce. Trade tensions involving tariffs implemented by President Trump have thus far focused on industrial manufacturing, with pharma companies largely untouched. “We now have nearly as many employees in the United States as in Germany.

  • Deleveraging Still Remains a Top Priority, Says Merck KGaA's CFO
    Bloomberg5 days ago

    Deleveraging Still Remains a Top Priority, Says Merck KGaA's CFO

    Marcus Kuhnert, chief financial officer at Merck KGaA, discusses second-quarter earnings, market share in liquid crystals, their M&A path and the drivers of their life sciences unit. He speaks on "Bloomberg ...

  • The Wall Street Journal6 days ago

    [$$] European Corporate Roundup for Thursday

    Adidas net profit rose, Thyssenkrupp swung to a Loss in 3rd quarter, Deutsche Telekom 2nd quarter net profit fell and Merck 2Q sales edged up.

  • Merck KGaA (MKGAF) Q2 Earnings Down Y/Y, Sales Flat
    Zacks6 days ago

    Merck KGaA (MKGAF) Q2 Earnings Down Y/Y, Sales Flat

    Merck KGaA (MKGAF) reports a mixed second-quarter with earnings declining year-over-year while sales remaining flat.

  • The Wall Street Journal6 days ago

    [$$] Merck 2Q Sales Edged Up

    KGaA (MRK.XE) backed its yearly forecast for sales Thursday after second-quarter group sales edged up slightly, despite being slowed down by currency headwinds. Its net income fell to EUR247 million from EUR426 million. According to consensus estimates compiled by FactSet, the company was expected to post sales of EUR3.63 billion, Ebitda of EUR961 million and net income of EUR567 million.

  • The Wall Street Journal6 days ago

    [$$] Merck KGaA Sales Edged Up, Confirms Outlook

    XE) backed its yearly forecast for sales Thursday after second-quarter group sales edged up slightly, despite being slowed down by currency headwinds. Its net income fell to €247 million from €426 million. According to consensus estimates compiled by FactSet, the company was expected to post sales of €3.63 billion, Ebitda of €961 million and net income of €567 million.

  • CNBC6 days ago

    Merck KGaA profit dragged lower by liquid crystal decline, forex

    Merck on Thursday reported 920 million euros ($1.07 billion) in second-quarter adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA), below market expectations of 960 million. Germany's Merck MERCK-IN KGaA saw adjusted core earnings decline 13.7 percent in the second quarter on lower revenues from liquid crystals used in flat screens and a strong euro weighing on the value of overseas sales.

  • Reuters6 days ago

    Merck KGaA profit dragged lower by liquid crystal decline, forex

    FRANKFURT (Reuters) - Germany's Merck KGaA (MRCG.DE) saw adjusted core earnings decline 13.7 percent in the second quarter on lower revenues from liquid crystals used in flat screens and a strong euro ...

  • What's in the Cards for Merck KGaA (MKGAF) in Q2 Earnings?
    Zacks8 days ago

    What's in the Cards for Merck KGaA (MKGAF) in Q2 Earnings?

    Merck's (MKGAF) Healthcare and Life Science segments are expected to drive sales in Q2. However, higher operating expense to support Bavencio and Mavenclad launch is expected to weigh on performance.

  • The Wall Street Journal15 days ago

    [$$] FDA Agrees to Review Merck Drug for MS Again

    KGaA’s (MRK.XE) resubmission for approval of a drug used to treat multiple sclerosis, the company said Monday. The move to review cladribine, which trades globally under the name Mavenclad, comes after the FDA nixed the company’s submission in 2011 on the grounds that there wasn’t enough data on safety. Merck said the FDA decided to grant the drug a “substantive review” after the regulator was given a beefed-up dossier with 12,000 patient years of data, including up to 10 years of data in some individual patients.

  • Reuters20 days ago

    UPDATE 3-Top EU court: GMO rules cover plant gene editing technique

    Crops obtained by plant breeding technique mutagenesis should fall under laws restricting the use of genetically modified organisms (GMOs), Europe's highest court said on Wednesday, in a victory for environmental campaigners. The biotech industry had argued that much of mutagenesis, or gene editing, is effectively little different to the mutagenesis that occurs naturally or is induced by radiation - a standard plant breeding method since the 1950s, but the court disagreed.

  • Reuters25 days ago

    Swiss, German drugmakers join U.S. price freeze

    European drugmakers Roche , Bayer and Merck KGaA became the latest companies to freeze prices in the United States for the rest of 2018 following criticism by President Donald Trump over the cost of medicine. Roche did boost U.S. prices for nine key drugs by an average of 3 percent on July 1, but said it would hold off additional increases as discussions with the Trump administration continue over a longer-term solution to containing healthcare costs.

  • Reuters25 days ago

    Swiss, German drugmakers join U.S. price freeze

    European drugmakers Roche (ROG.S), Bayer (BAYGn.DE) and Merck KGaA (MRCG.DE) became the latest companies to freeze prices in the United States following criticism by the Trump administration of the cost of medicine. Roche, Bayer and Merck KGaA all said on Friday they would not seek to lift prices this year in the world's biggest drug market, following Novartis (NOVN.S), Pfizer (PFE.N) and U.S. drugmaker Merck (MRK.N) which had already announced similar moves.

  • Associated Press28 days ago

    Lab-grown meat could be in restaurants in 3 years

    BERLIN (AP) — A Dutch company that presented the world's first lab-grown beef burger five years ago said Tuesday it has received funding to pursue its plans to make and sell artificially grown meat to restaurants from 2021.

  • The Wall Street Journal29 days ago

    [$$] Startup Producing Cell-Grown Meat Raises New Funding

    and a top European meat processor are backing a startup producing beef from cattle cells, ramping up a race to transform the global meat industry with cell-culture technology. fuels a continuing effort to fulfill growing global demand for meat via a process that developers say requires a fraction of the resources used in traditional livestock and poultry production.

  • Moody'slast month

    Merck Financial Services GmbH -- Moody's affirms Merck KGaA's Baa1 ratings

    Moody's Investors Service, ("Moody's") has today affirmed the Baa1 long-term issuer rating of Merck KGaA (Merck). Moody's has also affirmed the ratings of Merck's short term issuer, senior unsecured Medium Term Note program and junior subordinated ratings at P-2, (P)Baa1 and Baa3 respectively.

  • Reuterslast month

    Germany's Merck sees performance materials unit turning corner in 2020

    Germany's Merck KGaA (MRCG.DE) said it expects its performance materials business to return to sales and earnings growth after next year as it tackles tough competition from Chinese rivals in the market for liquid crystals for flat-screen televisions. Average annual sales for the performance materials business are expected to grow by between 2 and 3 percent the year after next, said Merck, the world's leading supplier of liquid crystals ahead of Japan's JNC Corp and DIC Corp .

  • Reuters2 months ago

    FOCUS-AI ambulances and robot doctors: China seeks digital salve to ease hospital strain

    HANGZHOU, China/SHANGHAI, June 28 (Reuters) - In the eastern Chinese city of Hangzhou, an ambulance speeds through traffic on a wave of green lights, helped along by an artificial intelligence (AI) system and big data. The system, which involves sending information to a centralised computer linked to the city's transport networks, is part of a trial by Alibaba Group Holding Ltd. The Chinese tech giant is hoping to use its cloud and data systems to tackle issues hobbling China's healthcare system like snarled city traffic, long patient queues and a lack of doctors. Alibaba's push into healthcare reflects a wider trend in China, where technology firms are racing to shake up a creaking state-run health sector and take a slice of spending that McKinsey & Co estimates will hit $1 trillion by 2020.

  • Reuters2 months ago

    AI ambulances and robot doctors: China seeks digital salve to ease hospital strain

    HANGZHOU, China/SHANGHAI (Reuters) - In the eastern Chinese city of Hangzhou, an ambulance speeds through traffic on a wave of green lights, helped along by an artificial intelligence (AI) system and big data. The system, which involves sending information to a centralised computer linked to the city's transport networks, is part of a trial by Alibaba Group Holding Ltd. The Chinese tech giant is hoping to use its cloud and data systems to tackle issues hobbling China's healthcare system like snarled city traffic, long patient queues and a lack of doctors. Alibaba's push into healthcare reflects a wider trend in China, where technology firms are racing to shake up a creaking state-run health sector and take a slice of spending that McKinsey & Co estimates will hit $1 trillion by 2020.

  • The Wall Street Journal2 months ago

    [$$] Wednesday's European Corporate Roundup

    A takeover bid by JCDecaux and a profit warning from U.K. housebuilder Berkeley are Wednesday’s corporate highlights in Europe.

  • PR Newswire2 months ago

    Merck KGaA, Darmstadt, Germany Provides Update on Tepotinib Phase II Results in Advanced Hepatocellular Carcinoma

    DARMSTADT, Germany , June 11, 2018 /PRNewswire/ -- Not intended for UK-based media    Primary endpoints met in two clinical trials for investigational targeted therapy, tepotinib,   as a monotherapy   ...

  • PR Newswire2 months ago

    Merck KGaA, Darmstadt, Germany Presents Updated Clinical Results for Bifunctional Immunotherapy M7824 at ASCO 2018

    DARMSTADT, Germany , June 4, 2018 /PRNewswire/ -- ASCO Abstract # M7824 (TGF-ß trap/anti-PD-L1): 3007, 9017, 2566, TPS3130; Tepotinib (c-Met kinase inhibitor): 9082, 9016; M2698 (dual p70S6k/Akt inhibitor): ...

  • PR Newswire2 months ago

    Two-Year Update of Pivotal JAVELIN Merkel 200 Trial Shows Continued Durable Responses with BAVENCIO® (avelumab)

    CHICAGO , June 4, 2018 /PRNewswire/ -- Not intended for UK-based media   Two- year follow-up data on meaningful durable responses , overall survival (OS) and progression-free survival (PFS) to be presented ...